ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

被引：0

作者：

Hsu, Jingmei ^{[1
]}

Kumar, Anita J. ^{[1
]}

Carroll, Martin P. ^{[1
]}

Frey, Noelle V. ^{[1
]}

Shah, Nirav N. ^{[1
,2
]}

Jianhua, Zhao ^{[3
]}

Hexner, Elizabeth O. ^{[1
]}

Loren, Alison W. ^{[1
]}

Mangan, James K. ^{[1
]}

Perl, Alexander E. ^{[1
]}

Porter, David ^{[1
]}

Morrissette, Jennifer ^{[3
]}

Luger, Selina M. ^{[1
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[3] Hosp Univ Penn, Philadelphia, PA 19104 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] ASXL1 mutations in idiopathic cytopenias: determined significance?
Galvez, Carlos
Stein, Brady L.
LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 568 - 570
[32] PROGNOSTIC SIGNIFICANT OF ASXL1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES
Wang, S. Y.
Lin, Y.
Zheng, Y.
Wang, Z. C.
HAEMATOLOGICA, 2016, 101 : 501 - 501
[33] Prognostic Impact of ASXL1 Mutations in MDS and CMML
Sallman, David
Padron, Eric
Vaupel, Christine
Cluzeau, Thomas
Al Ali, Najla H.
Lancet, Jeffrey E.
Hall, Jeff
List, Alan F.
Komrokji, Rami S.
BLOOD, 2015, 126 (23)
[34] ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Metzeler, Klaus H.
Becker, Heiko
Maharry, Kati
Radmacher, Michael D.
Kohlschmidt, Jessica
Mrozek, Krzysztof
Nicolet, Deedra
Whitman, Susan P.
Wu, Yue-Zhong
Schwind, Sebastian
Powell, Bayard L.
Carter, Thomas H.
Wetzler, Meir
Moore, Joseph O.
Kolitz, Jonathan E.
Baer, Maria R.
Carroll, Andrew J.
Larson, Richard A.
Caligiuri, Michael A.
Marcucci, Guido
Bloomfield, Clara D.
BLOOD, 2011, 118 (26) : 6920 - 6929
[35] In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML
Schnittger, Susanne
Haferlach, Claudia
Nadarajah, Niroshan
Alpermann, Tamara
Meggendorfer, Manja
Perglerova, Karolina
Kern, Wolfgang
Haferlach, Torsten
BLOOD, 2014, 124 (21)
[36] STAG2-mutated AML patients: ASXL1 cohesin binding motif status and mutation landscape.
Scarpa, Frank J.
Paul, Madhuri
Wolfson, Wendy A.
Weiss, Lawrence M.
Funari, Vincent Anthony
Blocker, Forrest
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[37] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
Kakosaiou, K.
Daraki, A.
Apostolou, P.
Zachaki, S.
Pagoni, M.
Sambani, C.
Dimitriadis, G.
Papa, V.
Manola, K. N.
ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 80 - 80
[38] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
Kakosaiou, K.
Daraki, A.
Apostolou, P.
Zachaki, S.
Pagoni, M.
Sambani, C.
Dimitriadis, G.
Papa, V.
Manola, K. N.
ANNALS OF HEMATOLOGY, 2015, 94 : S80 - S80
[39] ASXL1 mutations in myelodysplatic syndromes and their cooperation with additional gene mutations in the progression to secondary acute myeloid leukemia
Chang, H.
Shih, Y. S.
Lin, T. H.
Huang, Y. H.
Liang, D. C.
Liang, S. T.
Kuo, M. C.
Wang, P. N.
Wu, J. H.
Shih, L. Y.
LEUKEMIA RESEARCH, 2013, 37 : S38 - S38
[40] RUNX1-MUTATED AML SHOW A HIGH FREQUENCY OF TRISOMY 8 AND TRISOMY 13 AND ARE ASSOCIATED WITH MUTATIONS IN ASXL1 AND COMPONENTS OF THE RNA-SPLICING MACHINERY
Stengel, A.
Kern, W.
Meggendorfer, M.
Perglerova, K.
Haferlach, T.
Haferlach, C.
HAEMATOLOGICA, 2016, 101 : 362 - 362

← 1 2 3 4 5 →